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Abstract
Background: Myocardial siderosis is the most common cause of death in patients with beta thalassemia major(TM). This
study aimed at investigating the occurrence, prevalence and severity of cardiac iron overload in a young Chinese population
with beta TM.
Methods and Results: We analyzed T2* cardiac magnetic resonance (CMR), left ventricular ejection fraction (LVEF) and
serum ferritin (SF) in 201 beta TM patients. The median age was 9 years old. Patients received an average of 13 units of
blood per year. The median SF level was 4536 ng/ml and 165 patients (82.1%) had SF.2500 ng/ml. Myocardial iron
overload was detected in 68 patients (33.8%) and severe myocardial iron overload was detected in 26 patients (12.6%).
Twenty-two patients #10 years old had myocardial iron overload, three of whom were only 6 years old. No myocardial iron
overload was detected under the age of 6 years. Median LVEF was 64% (measured by CMR in 175 patients). Five of 6
patients with a LVEF,56% and 8 of 10 patients with cardiac disease had myocardial iron overload.
Conclusions: The TM patients under follow-up at this regional centre in China patients are younger than other reported
cohorts, more poorly-chelated, and have a high burden of iron overload. Myocardial siderosis occurred in patients younger
than previously reported, and was strongly associated with impaired LVEF and cardiac disease. For such poorly-chelated TM
patients, our data shows that the first assessment of cardiac T2* should be performed as early as 6 years old.
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Introduction
Myocardial siderosis remains the most common cause of death
in patients with beta thalassemia major (TM) [1]. In affluent
countries such as the UK, there has been a dramatic improvement
in survival since the introduction of cardiovascular magnetic
resonance(CMR) for assessment of myocardial iron [2], but iron
induced cardiomyopathy still accounts for the majority of all
deaths [3]. Early detection of myocardial iron overload is
important because survival is only 50% once overt heart failure
is manifest [4] and patients remain asymptomatic until late in the
course of development of iron overload cardiomyopathy. Usefully,
noninvasive CMR can quantify iron overload in different organs
such as the heart and liver even before the development of
symptoms [5,6]. In this regard, CMR relaxometry T2* is being
increasingly used worldwide for monitoring transfusion-dependent
TM [7,8].
The guidelines for the clinical management of thalassemia
edited by Thalassemia international federation (TIF) recom-
mended that the first assessment of cardiac T2* would be done
at puberty for the well-chelated patients who received chelation
therapy early and regularly [9], but there is not a specific guideline
for poorly-chelated patients. Most TM patients in developing
countries including China are poorly-chelated and many of them
die in childhood or early adolescence due to the lack of access to
specialist care [10,11]. For poorly-chelated patients, there is
limited data on when the myocardial siderosis occurs and when
the CMR T2* screening should be initiated. To answer these
questions, we designed this study to determine the age when
cardiac iron overload occurs and the prevalence of abnormal
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cardiac MRI T2* and myocardial function on a large young TM
population in mainland China.
Materials and Methods
Study Population
We studied 201 TM patients (192 children and 9 adults) from
November 2010 to January 2013. The median age was 9 (4–25)
years old. All patients were transfusion-dependent and required
transfusions from early childhood. Thirty-five patients (17.4%)
received splenectomy. Five patients (2.5%) were well-chelated and
196 patients (97.5%) were poorly-chelated. Patients were consid-
ered to be well-chelated if the following criteria were met [12,13]:
(i) initiate treatment after first 10–20 transfusions or serum ferritin
(SF) level above 1000 ng/ml; (ii) chelators dose: Deferoxamine
(DFO) is 20–40 mg/kg/day in children and 50–60 mg/kg/day in
adults, at least 5 days a week. Deferiprone (DFP) is 75 mg/kg/day.
Deferasirox (DFX) is 20–40 mg/kg/day; (iii) good compliance
with chelation therapy, defined as a$90% adherence to the
instructions given by the hematologists. The study was performed
at the first affiliated hospital of Guangxi Medical University.
Restrospective review of medical records, coded exchange of
clinical data, SF levels and MRI examininations were authorized
by the local institute. All of patients provided their written
informed consent to participate in this study. Adults ($18) finished
the informed consent by themselves. And for minors (,18), the
informed consents were obtained from the guardians on the behalf
of the minors participants involved in this study. The study was
approved by the Medical Ethics Committee of First Affiliated
Hospital of Guangxi Medical University (the approval number:
NO. 2008(KY-002).
Serum Ferritin
Laboratory blood tests were performed 2 weeks after the last
blood transfusion, followed by MRI evaluations with a 1-month
interval in all patients. Measurements were carried out by an
Electrochemiluminescence immunoassay (COBASE E 601, Roch,
USA).
MRI Protocols
Patients were scanned with a 1.5T MRI scanner (Siemens
Avanto, Siemens Medical Systems, Erlangen, Germany) with the
combination of body-matrix and spine-matrix surface coils. To
ensure quality of the work, the local staff involved in this study
(technicians, radiologists, and hematologists) received intensive
onsite training from CMR specialists of Royal Brompton Hospital
(London, UK). Each scan included the measurement of heart T2*
and left ventricular ejection fraction (LVEF) using previously
published techniques [14,15,16]. For T2* imaging, a single short
axis mid-ventricular slice was acquired at eight echo times (2.97–
21.68 ms) using a gradient-echo sequence within a single breath-
hold. For myocardial T2* measurement, a homogeneous full
thickness region of interest was chosen in the septum and signal
intensities at lengthening echo times analysed using a truncation
model [17]. LVEF were determined from steady-state free
precession cines using CMR tools (Cardiovascular Imaging
Solutions, London, UK).
Statistical Analysis
Data were expressed as mean6 one standard deviation, or
median (range) as appropriate. Mann Whitney U test or t test were
used for comparison of continuous variables between groups. The
significance of the correlation between parameters was assessed
using Spearman rank as the data was not normally distributed.
Categorical data were compared using the chi-square test.
Multivariate analysis used multiple linear regression analyses.
Statistical analyses were carried out using SPSS Statistics 13.0
(SPSS Inc., USA). A p value less than 0.05 was considered
statistically significant, and all p values were two sided.
Results
Patients
The main characteristics of these patients along with the main
results of the study were summarized in Table 1.
Table 1. The main characteristics of Chinese TM patients
along with the main results of the study.
Patients(n =201)
Male [n (%)] 125(62.2)
Ethnicity
Han 161
Other 40
Median age (range),years 9(4–25)
Age group, years
,6 [n (%)] 14(7)
6–,10 [n (%)] 89(44.2)
10–,15 [n (%)] 79(39.3)
15–,20 [n (%)] 14(7)
20–,25 [n (%)] 5(2.5)
Previous chelation therapy, [n (%)]
DFO 42(20.9)
DFP 25(12.4)
DFO+DFPa 95(47.3)
DFX 8(4)
DFO+DFXb 20(9.9)
None 11(5.5)
Mean 6 SD number of transfusions 116.3691.4
Median SF ng/mL (range) 4536(524.7–23,640)
SF category [n (%)]
,2500 ng/mL 36(17.9)
$2500 ng/mL 165(82.1)
cardiac T2*, ms 25.5612.5
T2* category [n (%)]
,10 ms 26(12.9)
10–20 ms 42(20.9)
.20 ms 133(66.2)
LVEF, [%] 64.865.6
LVEF category [n] 175
,56% [n (%)] 6(3.4)
$56% [n (%)] 169(96.6)
DFO,deferoxamine; DFP, deferiprone; DFX, deferasirox; SD, standard
deviation; SF, serum ferritin; LVEF, left ventricular ejection fraction.
a: patients received both DFO and DFP as prior chelation therapies, but these
may not have been in combination.
b: patients received both DFO and deferasirox as prior chelation therapies, but
these may not have been in combination.
doi:10.1371/journal.pone.0085379.t001
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Serum Ferritin
The median SF level of the patients was 4536 (525–23,640) ng/
ml. The SF was .2500 ng/ml in 165 patients (82.1%). There was
a significant correlation between SF and the total transfusion units
(r = 0.175, p = 0.013). A similar result was found in the correlation
between SF and age (r = 0.144, p = 0.042).
Cardiac T2*
The mean cardiac T2* value was 25.5612.5 ms (4.5–58.7 ms)
for all 201 patients. Cardiac T2*#20 ms were detected in 68
patients (33.8%), and cardiac T2*,10 ms were detected in 26
patients (12.6%). For patients #10 years old (n = 113), 32 patients
(28.3%) had cardiac T2*#20 ms, 3 of whom were only 6 years
old. Fourteen patients of 5 years of age and younger were scanned,
all with normal cardiac T2*.20 ms (Table 2). The five well-
chelated patients all had cardiac T2*.20 ms. The mean cardiac
T2* and incidence of cardiac T2*,10 ms in 161 Han ethnicity
patients was not significantly different with 40 other ethnicity
patients (25.8612.7 vs 23.6611.9, p= 0.311;33.5% vs
37.5%,p= 0.637).Cardiac T2* was negatively associated with age
(Fig. 1, r =20.328, p = 0.000) and the total units transfused (Fig. 2,
r =20.360, p = 0.000), respectively. A similar result was found in
the correlation between cardiac T2* and SF (Fig. 3, r =20.319,
p = 0.000). Multivariate analysis confirmed the negative correla-
tion between cardiac T2* and total units transfused (b=20.297,
P= 0.006), and SF (b=20.234, P = 0.000), but the non-correla-
tion between cardiac T2* and age (b=20.081, P = 0.421).
Left Ventricle Ejection Fraction (LVEF)
LVEF was measured by CMR in 175 patients and the median
of LVEF was 64% (49%–81%). Twenty-six young patients failed
to measure LVEF because they could not comply sufficiently with
breath-hold instructions. Six patients (3.4%) had LVEF,56% [6].
The median LVEF of 62 patients with cardiac iron overload
(T2*,20 ms) was not significantly different from those 113
patients without cardiac iron overload (T2*.20 ms) (65.5% vs
63%, p= 0.146). LVEF,56% was seen in 5 patients (8.1%) with
cardiac iron overload, comparing with only 1 (0.9%) without
cardiac iron overload (p = 0.021. Three patients with LVEF,56%
were under 10 years old. No correlation was found between LVEF
Figure 1. Correlation between cardiac T2* and age in Chinese TM patients. The dotted line represents cardiac T2* of 20 ms. The solid line
represents age of 6 years old. Cardiac T2* was negatively associated with age (r =20.328, p = 0.000) in these patients.
doi:10.1371/journal.pone.0085379.g001
Table 2. T2* information of patients divided into five-year
age groups.
T2* category Age groups, n (%)
#5 y 6–10 y 11–15 y 16–20 y .20 y
.20 ms 14(100) 81(71.7) 27(48.2) 9(64.3) 2(50)
10–20 ms 0 23(20.3) 14(25.0) 4(28.6) 1(25)
,10 ms 0 9(8.0) 15(26.8) 1(7.1) 1(25)
doi:10.1371/journal.pone.0085379.t002
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and SF (r = 0.111, p = 0.145) or LVEF and cardiac T2*
(r =20.147, p= 0.052) in these 175 patients (Fig. 4).
Cardiac Disease
A patient requiring cardiac medications, or with a LVEF,56%,
or with persistent arrhythmia [18,6] was considered to have a
cardiac disease. Ten patients (5%) had cardiac disease, 3 with
heart failure hospitalization, 1 with junctional rhythm, and 6 with
impaired LV systolic function (LVEF,56%). Among them, 8
patients had cardiac iron overload; of the two patients with normal
cardiac iron, one had myocarditis and the other junctional rhythm
disturbance. None of the well-chelated patients had cardiac
involvement. Four patients with cardiac involvement were under
10 years old. Three heart failure patients had cardiac iron
overload but LVEF.56% (63%, 68% and 68%). The patient with
junctional rhythm had both a normal cardiac T2* and a normal
LVEF.
Discussion
Iron induced cardiomyopathy can be reversed if aggressive
chelation begins early [19,20]. Thus, early detection of myocardial
iron deposition is imperative to prevent overt heart failure. In non-
chelated patients receiving regular transfusions, cardiomegaly
develops by the age of 10 years and heart failure by the age of 16
years [21]. The duration of life after the onset of failure was less
than 3 months in over half of the patients. Clinical diagnosis is
often delayed due to the typically late onset of symptoms. Iron
overload in TM occurs due to a combination of repeated blood
transfusions and excessive gastrointestinal absorption. Little is
known about the natural history of iron deposition in the heart.
Previous studies suggested that myocardial deposition takes place
after a minimum of 75 blood transfusions [22,23]. Assessment of
myocardial iron is essential clinically but conventional noninvasive
techniques are less than ideal. Endomyocardial biopsy is invasive
and not reliable because myocardial iron deposition is not
homogeneous [24,25]. Even the combination of SF, liver iron
concentration and ventricular function can only detect heart
failure at a late stage [26,27,28]. Usefully, cardiac T2* can be used
to monitor cardiac iron overload non-invasively, reproducibly and
accurately. However, cardiac T2* data on children younger than
10 years is rather limited. Wood et al recently reported from a
cohort of 77 TM patients in Italy and US that no cardiac iron was
observed under the age of 9.5 years [29]. In another earlier report,
it was suggested that cardiac iron overload occurred only after at
least 13 years of chronic transfusion therapy [18]. These studies
however, were based on well-chelated patients. Fernandes et al
recently reported a single patient with cardiac iron overload at the
age of 7 years but this study was limited to only 23 patients with
TM and other forms of anemia [30]. In our study, the vast
majority of patients (97.5%) had not received a good standard of
chelation therapy. Cardiac iron overload was found in patients
under 10 years old with severe cardiac iron overload in a
proportion, associated with impaired LVEF and cardiac symp-
Figure 2. Correlation between cardiac T2* and total units of blood transfused in Chinese TM patients. Cardiac T2* was negatively
associated with units of transfused blood(r =20.360, p = 0.000).
doi:10.1371/journal.pone.0085379.g002
Myocardial Iron Overload in Thalassemia Major
PLOS ONE | www.plosone.org 4 January 2014 | Volume 9 | Issue 1 | e85379
toms. We detected severe myocardial siderosis in patients as young
as 6 years old.
The median age of our TM patients was 9 (4–25) years old. The
median SF level was 4536 ng/ml and 165 patients (82.1%) had
SF.2500 ng/ml. The data confirmed our previous finding that
Chinese TM patients were younger and had greater burden of
iron overload than those in western countries [31]. Myocardial
iron overload was detected in 33.8% of our patients. This value
was lower than that reported in west countries, where cardiac
T2*,20 ms were seen in 32%–65% of adults with TM [32,33,16].
One explanation was that our patients were much younger and
most of them were children, but it is also notable that the average
yearly units transfused was only 13 per patient. SF was positive
associated with age. Cardiac T2* was negatively associated with
age and with SF. This finding was in contrast to other reports
showing no relation between cardiac T2* and SF in patients
chelated from a young age with a variety of different regimes, in
which the varying regimes may have resulted in the loss of
relationship between cardiac T2* and SF. For instance it is
recognized that DFO results in preferential chelation from the
liver whereas Deferiprone may be more effective for chelation of
cardiac iron. The younger age and lower levels of chelation
therapy may account for the discrepancy between our and
previous studies [34,35,33].
To our knowledge, this was the first cardiac T2* study on a
large and poorly-chelated and modestly transfused TM popula-
tion. The results may help develop guidelines to the clinical
assessment and management of iron overload in TM patients in
developing countries. It is estimated that more than 300,000
children are born annually with severe inherited disorders of
hemoglobin and approximately 80% of these births occur in low-
or middle-income countries [36,37]. Over the next 20 years
approximately 100,000 cases of Hb E/bthalassaemia will be added
to the Thailand population and 20,000 beta TM babies will be
born each year in China [38,39]. It is a global public health
challenge particularly in developing countries. In low- or middle-
income countries, many TM children receive inadequate iron
chelating therapy and many of them die as teenagers due to the
effects of iron overload [10]. Bejaoui M et al studied 391 TM
patients in Tunisia. They found that the mean age of death was
10.48 years with heart failure as the major cause of death [40]. A
disturbing study of 106 TM patients in Baise City (Guangxi,-
China), showed that 85 patients (80%) died before the age of 5
years [11]. At present, TM patients older than 30 years old are
seldom found in mainland China. The current life expectancy of
TM patients is unclear. While progress has been made for the
control and genetic screening for thalassemia trait over the last
decade in China, health care for patients suffering with TM in
China continues to pose a great challenge to the public health
services. Many factors, including the lack of disease specific
knowledge, shortage of blood, limited availability of chelators, lack
of specialist physicians and the limited resources within the health
insurance system pose challenges to optimum care. Although
health insurance coverage has increased dramatically over the last
Figure 3. Correlation between cardiac T2* and serum ferritin(SF) values in Chinese TM patients. Cardiac T2* was negatively associated
with SF (r =20.319, p = 0.000). The dotted line represents reference range for cardiac T2* of 20 ms, and the solid line represents SF of 2500 ng/ml.
doi:10.1371/journal.pone.0085379.g003
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decade in China, from 15% in 2000 to 96% in 2011, the financial
protection remains insufficient [41]. Although DFO has been used
for over 40 years in Western countries, it has only been available in
China since 1998. DEP and DFX were introduced to China in
2003 and 2010, respectively. Further, CMR T2* was first
introduced to China in 2010 and only a small number of TM
patients have benefitted from this technique. In brief, developing
countries lag far behind developed countries in the control and
management of thalassemia. It is therefore vital that international
health agencies and governments of countries where these diseases
are common start to develop the partnerships between rich and
low-income countries and establish specific guidelines towards the
most economic and effective approach to control and manage
thalassemia.
In conclusion, we present the findings of a large cohort of
Chinese TM children and adolescents. The vast majority of
patients are poorly-chelated and as a result of relative chelation
naivety, clear associations can still be demonstrated between
cardiac iron stores and age and serum ferritin. Myocardial
siderosis is strongly associated with impaired LVEF and heart
failure. Our results show the effects of poor chelation of young
patients and that the first assessment of cardiac T2* should take
place as early as 6 years of age.
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